FENC | Ticker Profile - Titan Protect

FENC

Fennec Pharmaceuticals Inc.

Healthcare · Biotechnology · NCM

$8.70

Data: 2026-05-15

✓ ETHICAL PASS

WEAK MOAT

HIGH

Data Confidence: 85.7%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$340M

Total market value of the company

Trailing P/E

N/A

Forward P/E

9.43

Based on estimated future earnings — lower means cheaper

Rev Growth

+72.6%

Year-over-year revenue change

Profit Margin

-16.4%

How much profit the company keeps from each dollar of revenue

ROE

-52.7%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$15.17

+74% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 6 analysts covering this stock

About Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment; and Norgine Pharma UK Limited. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

https://www.fennecpharma.com

Country: United States Employees: 35 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PASS

Debt must be below 33% of total assets

Cash Ratio

11.5% PASS

Interest-bearing cash below 33% of assets

Receivables

0.0% PASS

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Valuation

Fair Value Est.

$31.15

What our model estimates this business is worth per share

Margin of Safety

72.1%

Deep discount to fair value — significant undervaluation

Rating

OPPORTUNITY

Overall assessment combining ethics, valuation, and quality

Percentile

99.2th

Ranks in the top 1% of our 13,571 screened universe

Ethical Score

95.7

Valuation Score

95.0

Quality Score

33.8

Combined

79.3

Trading at $10 against a fair value of $31, a 69% discount. Passes all ethical screens. Ranks better than 98% of screened stocks.

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

0.579

Good returns relative to risk taken

Kelly Fraction

0.0239

Modest edge detected — smaller position warranted

Calmar Ratio

0.418

Drawdown risk outweighs the returns — higher risk profile

Annual Return

18.8%

Historical annualised return based on price data

Max Drawdown

-45.0%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.91

Less volatile than the market — more defensive

52W High

$10.17

14% below the year high

52W Low

$5.65

54% above the year low

Avg Volume

208,941

Average daily shares traded — higher means easier to buy and sell

Short Ratio

7.1

Days it would take all short sellers to cover — higher means more crowded

Short % Float

3.5%

Low short interest — limited bearish positioning

Div Yield

0.0%

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.34

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

0.00

Conservative use of debt — low financial risk

Current Ratio

6.98

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

6.15

Like current ratio but excludes inventory — stricter test

Gross Margin

92.2%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-0.8%

Profit from core operations before interest and tax

Free Cash Flow

N/A

Negative — the business is spending more than it generates

Revenue (TTM)

$51M

Total revenue over the last 12 months

Net Income

$-8,375,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$18.00

Target Median

$15.17

Target Low

$13.00

Recent Insider Activity

SEC Form 4 filings — what company insiders are buying and selling

Date	Insider	Title	Shares	Value
2026-05-11	RALLIS CHRISTOPHER ANIGERON	Director	14,344	$34,999
2026-05-11	RALLIS CHRISTOPHER ANIGERON	Director	8,346	$58,756
2026-05-01	RAYKOV ROSTISLAV CHRISTOV	Director	18,376	$38,215
2026-05-01	RAYKOV ROSTISLAV CHRISTOV	Director	10,781	$69,753
2026-04-30	CIOFFI CHRISTIANA MARIE	Officer	155	—
2026-04-30	EVANS TERRY L	Officer	168	—
2026-04-30	HACKMAN JEFFREY S	Chief Executive Officer	1,159	—
2026-04-30	SAYAD PIERRE SARGIS PH.D.	Officer	168	—
2026-04-30	ANDRADE ROBERT C	Chief Financial Officer	1,703	—
2026-04-01	RAYKOV ROSTISLAV CHRISTOV	Director	15,598	$38,215

Source: SEC Form 4 filings via public data. View all insider activity at

Insider Intelligence

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-15

Before you go